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Synthetic triterpenoid induces
15-PGDH expression and suppresses
inflammation-driven colon carcinogenesis
Sung Hee Choi,1 Byung-Gyu Kim,1 Janet Robinson,1 Steve Fink,2 Min Yan,2 Michael B. Sporn,3
Sanford D. Markowitz,2 and John J. Letterio1
1
Department of Pediatrics, Case Comprehensive Cancer Center, Case Western Reserve University,
The Angie Fowler Adolescent and Young Adult Cancer Institute, Cleveland, Ohio, USA. 2Department of Medicine and Case Comprehensive Cancer Center,
Case Western Reserve University and Case Medical Center, Cleveland, Ohio, USA. 3Department of Pharmacology,
Dartmouth Medical School, Hanover, New Hampshire, USA.

Colitis-associated colon cancer (CAC) develops as a result of inflammation-induced epithelial transformation, which occurs in response to inflammatory cytokine-dependent downregulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and subsequent suppression of prostaglandin metabolism. Agents that
both enhance 15-PGDH expression and suppress cyclooxygenase-2 (COX-2) production may more effectively
prevent CAC. Synthetic triterpenoids are a class of small molecules that suppress COX-2 as well as inflammatory cytokine signaling. Here, we found that administration of the synthetic triterpenoid 2-cyano-3,12-dioxo
oleana-1,9(11)-dien-C28-methyl ester (CDDO-Me) suppresses CAC in mice. In a spontaneous, inflammationdriven intestinal neoplasia model, deletion of Smad4 specifically in T cells led to progressive production of
inflammatory cytokines, including TNF-α, IFN-γ, iNOS, IL-6, IL-1β; as well as activation of STAT1 and STAT3;
along with suppression of 15-PGDH expression. Oral administration of CDDO-Me to mice with SMAD4deficient T cells increased survival and suppressed intestinal epithelial neoplasia by decreasing production of
inflammatory mediators and increasing expression of 15-PGDH. Induction of 15-PGDH by CDDO-Me was
dose dependent in epithelial cells and was abrogated following treatment with TGF-β signaling inhibitors
in vitro. Furthermore, CDDO-Me–dependent 15-PGDH induction was not observed in Smad3–/– mice. Similarly, CDDO-Me suppressed azoxymethane plus dextran sodium sulfate–induced carcinogenesis in wild-type
animals, highlighting the potential of small molecules of the triterpenoid family as effective agents for the
chemoprevention of CAC in humans.
Introduction
Epidemiologic data have shown an increasing burden of inflammatory bowel disease (IBD), with an estimated 1.7 million individuals in the United States suffering from IBD and IBD-associated
conditions (1–3). The 2 major subtypes, including ulcerative colitis and Crohn’s disease, are characterized by chronic, relapsing
inflammation of the gastrointestinal tract (4, 5). Uncontrolled
intestinal inflammation is characterized by overproduction of
inflammatory cytokines and trafficking of effector leukocytes
into the intestinal mucosal microenvironment. In humans, IBD
ranks among the top 3 high-risk conditions for colorectal cancer,
and affected individuals have a 10-fold greater risk of colon cancer over age-matched controls (6). Under homeostatic conditions
in the intestinal mucosa there is a state of “controlled” immune
cell activation and response in which there is a balance between
proinflammatory (TNF-α, IFN-γ, IL-1, IL-6, and IL-12) and antiinflammatory cytokines (IL-4, IL-10, and TGF-β). Unchecked
expression of proinflammatory cytokines, chemokines, and other
chemical mediators underlies the chronic inflammatory state
found in IBD (7–9). These proinflammatory cytokines are implicated in inflammation-associated gastrointestinal tumorigenesis
through their capacity to activate NF-κB, AP-1, STAT1, and
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STAT3 transcription factors, thereby promoting epithelial cell
proliferation, survival, invasion, and metastasis.
The enzyme NAD-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) plays a major role in catabolism of the naturally occurring prostaglandin E2 by oxidizing the 15-hydroxyl
group of prostaglandins to inactive 15-keto metabolites (10, 11).
The human PGDH gene is located on chromosome 4 and encodes
a 29-kDa protein. 15-PGDH is highly expressed in normal colon
epithelia but the expression is decreased in colon cancers (12–15).
15-PGDH has a demonstrated tumor suppressor activity in lung
cancer and breast cancer (16, 17), and overexpression of 15-PGDH
inhibits growth of colon tumor xenografts in immune-deficient
mice (13). Expression of 15-PGDH is induced in colon epithelial
cells by treatment with TGF-β, a cytokine known to activate an
important tumor suppressor pathway in colon cancer (13, 18, 19).
However, the mechanisms underlying this induction of 15-PGDH
by TGF-β have not been defined clearly.
Recent studies have demonstrated the role of inflammatory
cytokines in the suppression of 15-PGDH expression in IBD. For
example, work by Otani and colleagues revealed that 15-PGDH
protein and mRNA are markedly reduced in the inflamed
mucosa of patients with IBD (20). This phenomenon was
attributed to the actions of TNF-α, which suppressed transcription of 15-PGDH in human colonocytes, while inducing COX-2
and microsomal prostaglandin E synthase-1. In a more recent
study, hemokinin-1, a tachykinin produced by immune cells and
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Figure 1
Smad4Tko mice develop CAC. Biomarkers of disease progression were defined in wild-type and
Smad4Tko (KO) mice at 3 and 8 months of age.
(A) The colon weight per length of 3-month-old
or 8-month-old wild-type and Smad4Tko mice. (B)
Expression of proinflammatory cytokines (TNF-α,
IL-1β, IL-6, and IFN-γ) from colon epithelial cells
from wild-type or KO mice, as measured by
RT-PCR. (C) Phosphorylation of STAT1, STAT3,
and Iκb as well as expression of iNOS, COX-2,
and 15-PGDH, as detected by Western blot. (D)
Concentration of nitrate from sera of wild-type and
Smad4Tko mice. Analyses at 3 months include
wild-type mice (n = 4) and Smad4Tko mice (n = 5);
analyses at 8 months include wild-type (n = 7)
and Smad4Tko mice (n = 8). Results shown are
representative of 4 separate experiments.

upregulated in IBD, was shown to stimulate COX2 gene expression and repress 15-PGDH protein expression in colonic mucosal
explants (21). COX-2 induction was coupled with hemokinin-1–
induced downregulation of PGDH mRNA and protein expression,
suggesting again that hemokinin-1 may interfere with the downstream metabolism of prostaglandin E2 by suppressing 15-PGDH
expression in the setting of IBD (21).
The synthetic oleanane triterpenoid 2-cyano-3,12-dioxoolean1,9-dien-28-olic acid (CDDO) and its derivatives are small molecules with potent antiinflammatory and anticarcinogenic properties (22–29). The synthetic triterpenoids inhibit expression of
inflammatory mediators, such as inducible NOS (iNOS) and
inducible cyclooxygenase-2 (COX-2), through suppression of various inflammatory cytokines, such as IFN-γ, IL-1β, and TNF-α
(30, 31), and also by direct inhibition of the signaling intermediate STAT3 (32). Synthetic triterpenoids have also been shown to
enhance TGF-β/SMAD signaling by prolonging expression of the
receptor-activated p-SMAD2 through enhanced cell surface TGF-β
type II receptor expression (31, 33).
Here, we provide the first evidence that oral administration of
a triterpenoid potently suppresses colitis-associated colon cancer
(CAC) in mice. We show that oral administration of the synthetic
triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-C28-methyl
ester (CDDO-Me) markedly increased survival, reduced inflammation, and inhibited spontaneous colon tumorigenesis in mice
with a T cell–restricted deletion of the TGF-β signaling intermediate, SMAD4 (Lck-Cre Smadco/co [Smad4Tko] mice) (34), and in wildtype mice, which were tested with a classical model of carcinogenesis that combines the carcinogen azoxymethane (AOM) and an
inducer of inflammation, dextran sodium sulfate (DSS). CDDOMe administration suppressed the production of proinflamma-

tory cytokines and proinflammatory mediators such as iNOS
and restored the expression of 15-PGDH in intestinal epithelia.
Furthermore, we show the induction of 15-PGDH by CDDO-Me
in vivo is absent in mice with a germ line deletion of the Smad3 gene
(Smad3–/– mice) and is abrogated by inhibitors of TGF-β signaling
in vitro. These data support the further development of this class
of small molecules as potent, safe, and effective agents for the
chemoprevention of CAC.
Results
Loss of 15-PGDH expression, induction of COX-2 and iNOS, and activation of STAT signaling are all hallmarks of CAC in the Smad4Tko
mice. We previously established a novel murine model of CAC
through creation of a T cell–specific deletion of the Smad4 gene
in mice (34). In this model, selective loss of SMAD4-dependent
signaling in T cells leads to spontaneous intestinal inflammation
throughout the gastrointestinal tract. Smad4Tko mice invariably
develop CAC after 8 months of age, with inflammatory infiltration of the mucosa, loss of body weight, and bloody diarrhea. We
hypothesized that the development of CAC in this model is linked
to inflammation-driven activation of pro-oncogenic signaling
(NF-κB, STAT) and repression of important tumor suppressors,
including 15-PGDH; thus, here we investigate epithelial cell signaling in Smad4Tko mice. In Smad4Tko mice, colon thickness (colon
weight divided by length, expressed as g/cm) was twice that of
normal controls at 8 months of age (Figure 1A). Colon thickness
can be influenced by edema, thus this is merely supportive of the
histological and biochemical observations that we describe below.
Cytokines and chemokines that promote colitis-associated colon
tumor development include TNF-α, IL-6, IL-1, and CCL2 (7–9,
35), through mechanisms that include regulation of epithelial
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Figure 2
Oral administration of CDDO-Me
suppresses mucosal inflammation
in 8-month- old Smad4Tko mice. ( A)
Eight- month- old Smad4 Tko mice
were given CDDO-Me by gavage
every other day for 1 month. (B)
Mortality (n = 10 per group). ( C)
Percent weight change. ( D) Colon
histology (i and iii show sections
from Smad4Tko mice receiving control sesame oil; ii and iv show sections from Smad4 Tko mice treated
with CDDO-Me). (E) Colon weight
per length (g/cm) ( n = 9). Error bars
indicate SEM; *P < 0.05, **P < 0.01
compared with mice in control group
receiving sesame oil alone.

homeostasis and increased epithelial proliferation. The expression of proinflammatory cytokines, such as TNF-α, IL-1β, IL-6
and IFN-γ, was markedly elevated in the colons of Smad4Tko mice
at 8 months of age, relative to that in wild-type controls (Figure
1B). We observed a temporal relationship between the progressive
increase in the expression of these inflammatory cytokines and
the activation of NF-κB, STAT1, or STAT3 in intestinal mucosal
epithelia in Smad4Tko mice, as assessed by Western blot analysis. In
young mice (3 months of age), there was no difference observed
in p-STAT3, iNOS, COX-2, and 15-PGDH expression in wild-type
and Smad4Tko mice, consistent with an absence of enhanced inflammatory cytokine expression at this age. The phosphorylation of
STAT1 (activated by IFN-γ) was hardly detectable in the colons
of wild-type mice but was greatly increased in Smad4Tko mice at
8 months of age (Figure 1C). Overexpression of iNOS is a common phenomenon during chronic inflammation. While iNOS
induction was not detected in wild-type mice, it was substantially
increased in Smad4Tko mice (Figure 1C), strongly correlating with
an elevated serum nitrate concentration in Smad4Tko mice, reaching
a level 3 times greater than that in wild-type mice at 8 months of
age (Figure 1D). Previous reports have shown that the constitutive expression of 15-PGDH found in normal human colon mucosa
is undetectable in human colon cancers (13). In our studies, both
3-month-old wild-type and Smad4Tko mice had high expression of
15-PGDH, but, by 8 months of age, the Smad4Tko mice invariably
lost expression of 15-PGDH in colon mucosa (Figure 1C).
2474

Daily oral administration of CDDO-Me suppresses colitis-associated
colon tumorigenesis in Smad4Tko mice. There is increasing evidence
that the triterpenoid family of small molecules (both natural
and synthetic) target important signaling intermediates linked
to inflammation and cancer (25). To test whether the synthetic
triterpenoid CDDO-Me might serve as an effective chemopreventive agent in the context of CAC, CDDO-Me was given orally
to Smad4Tko mice and respective controls (250 ng per mouse per
day, 3 times per week for 1 month), beginning at 8 months of
age (see schema in Figure 2A). Smad4Tko mice receiving vehicle
alone (sesame oil) were used as a control group. The survival of
CDDO-Me–treated mice was 100% at 9 days from initiation of
therapy and 80% at the end of the experimental period, compared
with 60% and 10%, respectively, in the control group (Figure 2B).
Decreased survival in control mice correlated with an 8% reduction in weight not observed in the CDDO-Me–treated groups (Figure 2C). Furthermore, Smad4Tko mice receiving sesame oil only
(control group) displayed gross thickening and enlargement of
small and large intestines, rectal prolapse, and multiple polyps
(Figure 2D, images i and iii). Smad4Tko mice receiving CDDO-Me
had very normal appearing intestines at gross necropsy (Figure 2D,
images ii and iv). The colon weight per length (g/cm) of CDDOMe–treated mice (0.065 g/cm) was nearly fifty percent less than
that of control mice receiving sesame oil alone (0.12 g/cm) (Figure
2E). Sections of the intestines of Smad4Tko mice stained with H&E
also clearly demonstrate a difference in histopathology between
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Figure 3
Cancer chemoprevention by CDDO-Me in the Smad4Tko mouse model of CAC. ( A) Mucosal histology was examined in Smad4Tko mice treated
with either sesame-oil or CDDO-Me. Paraffin-embedded sections were stained with H&E. Scale bars: 200 μm. (B) Percentage of tumor-bearing mice. (C) Tumor number. (D) Tumor sizes were determined using a digital eyepiece. (E) Histogram showing size distribution of tumors.
(F) Expression of proinflammatory mediators in tumor and nontumor intestinal mucosa. Whole tumor specimens and adjacent mucosa samples
were homogenized. iNOS, p-STAT3, p-STAT1, COX-2, p-iκB, and β-actin expression were measured by Western blot. N, nontumor intestinal
mucosa; T, tumor tissue. ***P < 0.001.

recipients of CDDO-Me or vehicle control (Figure 3A). Colon
tumors were present in 92% of Smad4Tko mice. However, this tumor
incidence decreased significantly to 25% in the CDDO-Me–treated
group (Figure 3B). The multiplicity of colonic tumors (number
of tumors per mouse) was significantly decreased in CDDO-Me–
treated mice (0.71 per mouse) when compared with that in mice
receiving sesame oil alone (4.22 per mouse) (Figure 3C). Tumor size
was also reduced by exposure to CDDO-Me (0.75 mm) relative to
that in recipients of sesame oil alone (2.18 mm) (Figure 3, D and E).
As anticipated, we found that the expression of proinflammatory
mediators was not restricted to tumor tissue (Figure 3F), as the
expression of p-STAT1, p-STAT3, COX-2, and p-iκB was similar in
lysates of tumor and of adjacent intestinal mucosa.
Oral administration of CDDO-Me suppresses proinflammatory cytokine
production and epithelial cell proliferation, while inducing expression of the
tumor suppressor 15-PGDH. While triterpenoids exert direct antiproliferative effects, it is likely that suppression of mucosal epithelial
cell proliferation by CDDO-Me in our model would be linked to
suppression of inflammatory cytokine production and activation
of downstream signaling intermediates, including STAT1, STAT3,
NF-κB, and others (as shown in Figure 3F). Analysis of Ki-67–
positive cells in the intestinal crypts showed that exposure to
CDDO-Me significantly reduced epithelial cell proliferation in
the colons of Smad4Tko mice when compared with that in recipients
of sesame oil alone (Figure 4A). Production of proinflammatory
cytokines, IL-6 and IFN-γ, was substantially reduced by exposure to CDDO-Me (Figure 4B) and correlated with a reduction
in phosphorylation of STAT3 and STAT1 in colon epithelial cells
in mice exposed to CDDO-Me (Figure 4C). When we examined

the effects of CDDO-Me on the production of the inflammatory
mediator iNOS, we found iNOS protein expression and mRNA
transcript levels were greatly elevated in Smad4Tko mice receiving
sesame oil alone when compared with iNOS levels observed in wildtype mice and Smad4Tko mice exposed to CDDO-Me (Figure 4D).
Finally, we examined the relationship of exposure to CDDOMe to the expression of 15-PGDH (mRNA and protein) in
colon epithelia of Smad4Tko mice. While neither 15-PGDH protein or mRNA were detected in the Smad4Tko recipients of sesame oil alone, treatment with CDDO-Me for 1 month restored
15-PGDH expression to levels matching those observed in healthy
wild-type mice (Figure 4D). The serum nitrate concentration was
also reduced in recipients of CDDO-Me (Figure 4E).
CDDO-Me suppresses DSS-induced colitis and AOM/DSS-induced
colon carcinogenesis. Young Smad4Tko mice (at less than 3 months
old) appear healthy and do not show indications of inflammation,
such as high nitrate levels and production of proinflammatory
cytokines, and they have no clinical symptoms of colitis. Thus,
to develop this model further and to accelerate the onset of
disease, we used DSS to induce inflammation in Smad4Tko mice.
We exposed 8-week-old mice to 2% DSS in drinking water for
7 days, followed by administration of regular water for 10 days.
This cycle was repeated 3 times (Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/
JCI69672DS1). Exposure of Smad4Tko mice to 2% DSS resulted
in a substantial increase in production of proinflammatory
cytokines, such as IL-6 and IFN-γ, while Smad4Tko mice receiving
only normal drinking water did not show any increase in production of proinflammatory cytokines (Supplemental Figure 1B).
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Figure 4
CDDO-Me treatment suppresses inflammatory mediators and increases the expression of 15-PGDH in colon mucosa. Eightmonth- old Smad4Tko mice were treated with
either sesame oil or CDDO-Me (250 ng
per mouse per day) for 1 month. (A) The
percentage of Ki-67–positive cells among
all colon epithelium cells was determined
in mice treated with either sesame oil or
CDDO-Me. Data represent average ± SEM
(n = 9). ***P < 0.001 with direct comparison to Smad4Tko mice receiving sesame
oil alone. Scale bar: 100 μM. (B) Expression
of proinflammatory cytokines, IL-6 and IFN-γ,
was measured by RT-PCR. (C) Expression
of STAT1 and STAT3, phospho-STAT1, and
phospho-STAT3 was measured by Western blot (lanes were run on the same gel but
were noncontiguous). (D) Protein and mRNA
expression of iNOS and 15-PGDH were measured by Western blot and RT-PCR analysis (lanes were run on the same gel but were
noncontiguous). (E) Nitrate concentration in
sera of Smad4Tko mice receiving either sesame oil or CDDO-Me. Wild-type control mice
also received sesame oil (n = 9).

The phosphorylated forms of transcription factors STAT1 and
STAT3, which are activated by IFN-γ and IL-6, were greatly
increased in extracts of mucosal epithelia of DSS-treated Smad4Tko
mice (Supplemental Figure 1C). At this time point, there was neither induction of TNF-α expression nor a significant change in
activation of the TNF-α signaling intermediates observed. However, iNOS expression was considerably elevated in colonic epithelia of DSS- treated Smad4Tko mice, in which the expression of
the tumor suppressor 15-PGDH was also completely suppressed
(Supplemental Figure 1C). Last, serum nitrate levels were elevated
in Smad4Tko mice exposed to DSS (Supplemental Figure 1D).
To determine whether CDDO-Me might suppress induction of
colitis by DSS in Smad4Tko mice, CDDO-Me (250 ng per mouse per
day) was administered 3 times per week for 4 weeks (Supplemental Figure 2A). Histologic examination by H&E staining demonstrated suppression of the mucosal thickening and inflammation
in Smad4Tko mice by CDDO-Me treatment (Supplemental Figure
2B), correlating with a complete suppression of the expression
of proinflammatory cytokines, such as IL-6 and IFN-γ, and a
major reduction in p-STAT1 and p-STAT3 in the colonic mucosa
of Smad4Tko mice receiving CDDO-Me (Supplemental Figure 2,
C and D). Similarly, CDDO-Me suppressed the production of
iNOS and associated elevations in serum nitrate normally found
in DSS-treated Smad4Tko mice (Supplemental Figure 2, D and E).
Finally, the suppressed basal expression of 15-PGDH observed
in Smad4Tko mice exposed to DSS was restored to baseline by the
2476

administration of CDDO-Me (Supplemental Figure 2D). This restoration of 15-PGDH expression may be secondary to reversal of
the direct suppression of 15-PGDH expression by inflammatory
cytokines, as suppression of 15-PGDH by TNF-α in the context
of colitis has been suggested previously (20). Indeed, we showed
suppression of 15-PGDH expression in cultured epithelial cells
by IFN-γ in vitro (Supplemental Figure 3A). Direct suppression
of Pgdh gene expression by IFN-γ and IL-6 was demonstrated by
reporter assays, in which IFN-γ and IL-6 suppressed 15-PGDHluciferase activity in cells transfected with a 15-PGDH promoter
construct (Supplemental Figure 3B). CDDO-Me also suppressed
the production of IFN-γ and IL-6 by activated T cells (Supplemental Figure 3C). However, our data, thus far, do not rule out the
possibility that CDDO-Me might directly induce the expression of
15-PGDH in epithelial cells.
To support the relevance of our findings in the Smad4Tko model,
we examined the effects of CDDO-Me in the AOM/DSS inflammation-associated murine model of colon carcinoma. Mice (C57/BL6,
ages 6–8 weeks) received intraperitoneal injections with 10 mg/kg
AOM (NCI), followed by exposure to 2% DSS in drinking water
for 7 days (Figure 5A). We repeated 3 cycles of 2% DSS, with 10
days of normal drinking water provided between cycles. At the end
of 3 cycles, mice were sacrificed. The experimental group received
CDDO-Me on alternating days during DSS treatment, following
the same protocol used for the treatment of Smad4Tko mice. Weight
was measured daily during treatment, and colon tumors were
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Figure 5
Chemoprevention of AOM/DSS-induced colon cancer
by CDDO-Me. Body weight and tumor number in mice
treated with AOM/DSS or AOM/DSS plus CDDO-Me.
(A) Experimental procedure used to induce colon
cancer in C57BL/6 mice. After initial AOM injection
(10 mg/kg), DSS was given in drinking water, followed
by normal drinking water. Either CDDO-Me (250 ng
per mouse per day) or sesame oil were given to the
mice every other day during the DSS treatment. (B)
Changes in body weight among each group were
defined as follows: percentage = (final weight − initial
weight)/initial weight × 100. CDDO-ME treatment did
not affect the body weights. Tumors were enumerated
examined using a dissecting microscope at day 53.
(C) Images of colons at necropsy and (D) H&E staining of tumor morphology. Scale bar: 200 μM. (E) Colon
length and (F) number of tumors in sesame oil–treated
or CDDO-ME–treated groups. The sesame oil–treated
group had 10 mice, and the CDDO-ME–treated group
had 9 mice. Results are mean ± SEM. **P < 0.01.

enumerated at the time of sacrifice, as described in the Methods.
Mice receiving CDDO-Me experienced less change in body weight
compared with the sesame oil–treated group (Figure 5B). Repeated
DSS administration causes chronic inflammation, thereby mimicking IBD and greatly enhancing the incidence of AOM-induced
tumors (Figure 5C). CDDO-Me recipients showed marked protection from AOM/DSS-induced colon cancer (Figure 5, C and
D). Colon length, which shrinks with stress, inflammation, and
ulceration, was relatively well preserved in the experimental group
(7.5 ± 0.2 cm) when compared with that of mice receiving sesame
oil alone (5.8 ± 0.16 cm; Figure 5E) (P = 0.000002). The multiplicity
of colon tumors in the CDDO-Me–treated group was also significantly lower than that in sesame oil–treated group (Figure 5F).
Induction of 15-PGDH by the synthetic triterpenoid CDDO-Me in colon
epithelial cells in vitro. To pursue potential molecular mechanisms
mediating the cancer chemopreventive effects of CDDO-Me in
our model of CAC, we examined the effects of CDDO-Me on the
expression of 15-PGDH in the epithelial cell line, FET. Confluent
cultures of FET cells were treated for 24 hours with increasing
concentrations of CDDO-Me (10–300 nM), after which the levels
of 15-PGDH protein and mRNA expression were determined by
Western blot and by reverse transcription–PCR (RT-PCR) analysis,

respectively. A dose-dependent induction of the expression levels
of both 15-PGDH protein and mRNA transcripts by CDDO-Me
was observed (Figure 6A). The induction of 15-PGDH peaked at
48 hours after initiation of CDDO-Me treatment (Figure 6B). To
determine the effects of CDDO-Me on the transcriptional regulation of 15-PGDH, we investigated the luciferase activity of a
15-PGDH promoter-pGL3 gene reporter (a 2.2-kb 15-PGDH
promoter construct) in FET cells after CDDO-Me treatment. We
observed a 5-fold increase in 15-PGDH-pGL3 luciferase activity
following exposure to 300 nM CDDO-Me when compared with
control cultures (Figure 6C). These results indicate that CDDOMe can induce 15-PGDH expression through direct transcriptional regulation. This dose-dependent induction of 15-PGDH
expression paralleled a dose-dependent suppression of colon
epithelial cell proliferation by CDDO-Me, as determined by thymidine incorporation (Figure 6D). Previous reports have demonstrated the capacity of synthetic triterpenoids to augment the
response to TGF-β (31, 36, 37). Therefore, one interpretation of
our data might be that the observed induction of 15-PGDH by
CDDO-Me is dependent on activation of TGF-β signaling.
SMAD-dependent induction of 15-PGDH expression by CDDO-Me.
Previous reports have established 15-PGDH as a potential media-
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in a dose-dependent manner in the
colonic epithelia of Smad4Tko mice,
as determined by Western blot
analysis (Figure 7E). However, the
administration of CDDO-Me to
mice with a germ line deletion of
the gene encoding the TGF-β signaling intermediate, SMAD3, had
no effect on 15-PGDH expression
(Figure 7E). These results are consistent with in vitro experiments
and show that enhanced expression of 15-PGDH by CDDO-Me
is mediated, at least in part, by
activation of the TGF-β signaling
pathway. Similarly, the suppression
of FET cell proliferation by TGF-β
is enhanced by coadministration of
CDDO-Me, as determined by thymidine incorporation (Figure 7F).
Figure 6

Discussion
In this study, we have assessed the
role of 15-PGDH as a mediator of
the effects of a synthetic triterpenoid (CDDO-Me) in the suppression of colitis and colitis-associated
colon carcinogenesis. Our data provide the first direct demonstration
that CDDO-Me has specific and
potent chemopreventive activity in
CAC. We have observed a similar
response to related triterpenoids
(both natural and synthetic) in
this model, suggesting that this is
a property that extends to other
members of this class of small molecules (data not shown). Mice lacking Smad4 gene expression in T
cells (Smad4Tko mice) invariably develop inflammation in the colon,
which progresses to CAC. This phenotype is linked to a significant
production of proinflammatory mediators in colon epithelia. In
our Smad4Tko mouse model, the observed increases of IFN-γ and IL-6
lead to activation of STAT1 and STAT3 signaling and suppression
of 15-PGDH expression in colon epithelial cells and to increased
epithelial cellular proliferation. Oral administration of CDDO-Me
markedly suppressed production of proinflammatory cytokines
(IFN-γ and IL-6), a response linked to suppression of STAT1 and
STAT3 activation. The proinflammatory mediator iNOS and its
product NO were also suppressed by treatment with CDDO-Me.
The exploration of 15-PGDH as a therapeutic target has
started to gain interest (38). While our studies have focused
primarily on the role of 15-PGDH in suppressing colon carcinogenesis, recent studies suggest that 15-PGDH plays an important
role in gastric carcinogenesis as well (39). Gastric cancer cells stably transfected with a 15-PGDH siRNA plasmid have a higher
rate of proliferation, while stable transfection with a 15-PGDH
cDNA suppressed both growth rate, clone formation, and soft
agar colony formation of gastric cancer cells in vitro as well as
tumor formation in athymic nude mice in vivo (39). Agents that
specifically activate the expression of 15-PGDH have not been

CDDO-Me increases the expression of 15-PGDH in colon epithelial cells. (A) Expression of 15-PGDH
protein and mRNA after treatment with CDDO-Me. FET cells were treated with various doses of CDDOMe (0–300 nM) for 24 hours. Expression of 15-PGDH protein and mRNA was analyzed by Western
blotting and RT-PCR analysis (β-actin was used as a control). Lanes were run on the same gel but were
noncontiguous. The data shown are representative of 6 independent experiments. (B) Time-dependent
effect of CDDO-Me (100 nM) on 15-PGDH expression. FET cells were treated with CDDO-Me (100 nM)
for 6, 12, 24, 48, and 72 hours and analyzed by Western blot. The data shown are representative of
3 independent experiments. (C) CDDO-Me–induced 15-PGDH promoter luciferase activity. pGL3 and
15-PGDH promoter activity in FET cells following stimulation with CDDO-Me (300 nM) for 24 hours.
The fold induction of the relative levels of 15-PGDH transcripts was compared with that of untreated
pGL3 transcripts. A dual luciferase assay was performed, and data shown are averages of triplicate
independent measurements of Firefly/Renilla luciferase readings normalized to untreated controls.
Data represent average ± SEM (n = 4–6). (D) CDDO-Me inhibited colon epithelial cellular proliferation
in a dose-dependent manner. 5 × 103 FET cells were cultured with CDDO-Me (0–300 nM) in 96-well
plates with treatment, and proliferation was assessed by incorporation of 3H-thymidine.

tor of tumor suppression by TGF-β. In our studies, TGF-β (1 ng/
ml) increased expression of 15-PGDH in cultured colon epithelial
cells, and this induction was augmented in a dose-dependent manner by CDDO-Me (Figure 7A). The direct effect of CDDO-Me on
TGF-β signaling is further demonstrated by the dose-dependent
increase of SBE-luciferase reporter activity in FET cells exposed
to CDDO-Me. TGF-β induction of SBE-luciferase activity was
further potentiated by coadministration of CDDO-Me (Figure
7B). Phosphorylation of the TGF-β receptor-activated intermediates, SMAD2 and SMAD3, was observed in FET cells following
30 minutes of exposure to CDDO-Me (Figure 7C). To confirm that
the induction of 15-PGDH by CDDO-Me is mediated by TGF-β
signaling, we showed that pretreatment of FET cells with TGF-β
receptor inhibitors (SB431542 and IN1130) blocked the induction of 15-PGDH expression by CDDO-Me, TGF-β, or the combination in FET cells (Figure 7D). Similarly, the SMAD3- specific
inhibitor, SIS3, blocked induction of 15-PGDH by either CDDOMe or TGF-β (Figure 7D).
Last, we explored the requirement for SMAD signaling for
induction of 15-PGDH by CDDO-Me in vivo. Smad4Tko mice have
an intact TGF-β signaling system in the mucosal epithelia. As predicted, administration of CDDO-Me (either 1.25 or 5 μg given
by mouth, for a total of 2 doses) increased 15-PGDH expression
2478
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Figure 7
Induction of 15-PGDH expression by CDDO-Me requires SMAD-dependent TGF-β signaling. (A) FET cells cultured with CDDO-Me plus TGF-β
(1 ng/ml). Western blot is representative of 3 independent experiments (noncontiguous lanes were run on the same gel). Graphs represent the
mean ± SEM of 4 independent sets of experiments. (B) FET cells transfected with SBE-luc were treated with CDDO-Me plus TGF-β (1 ng/ml).
Results of a dual luciferase assay are shown as averages (triplicate independent measurements of Firefly/Renilla luciferase normalized to untreated controls). Results are representative of 3 different experiments. (C) FET cells were treated with either TGF-β or CDDO-Me (for
10 minutes to 9 hours) and phosphorylation of SMAD2 and SMAD3 was examined by Western blot. (D) Cells were incubated for 30 minutes with
either TGF-β receptor inhibitors, SB431542 (10 μM) or IN1130 (10 μM), or SMAD3-specific inhibitor, SIS3 (10 μM), before adding TGF-β (1 ng/ml)
and/or CDDO-Me (300 nM). Data represent 3 independent experiments (all noncontiguous lanes were run on the same gel). (E) CDDO-Me
failed to induce mucosal 15-PGDH expression in vivo in SMAD3 KO mice. Mice received CDDO-Me (1.25 μg or 5 μg) by gavage, and colon
epithelial scrapings were analyzed by Western blot 24 hours after the last dose (all noncontiguous lanes were run on the same gel). (F) Proliferation of FET cells (with or without CDDO-Me and/or TGF-β) was measured by incorporation of 3H-thymidine.

described. However, calcitriol (i.e., 1,25-dihydroxy-vitamin D,
ref. 3, the hormonally active form of vitamin D) suppresses COX-2
expression and induces expression of 15-PGDH, thereby reducing the levels of inflammatory prostaglandins in estrogen recep-

tor–positive breast cancer (40), and it has similar effects in prostate cancer (41). The requirement for the 15-PGDH pathway in
mediating the antiproliferative and tumor suppressor actions of
calcitriol is an area for further investigation. Our data implicate
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15-PGDH as a potential mediator of tumor suppression by the
SMAD-dependent TGF-β pathway.
There are likely multiple mechanisms leading to the loss of
15-PGDH expression in mucosal epithelial tumors, including
active suppression of PGDH gene transcription by proinflammatory cytokines like IFN-γ and TNF-α. The loss of 15-PGDH
expression may also result from impaired TGF-β signaling, a common event in colon and gastric cancers (42–44). While published
data support the concept that 15-PGDH plays a direct role in controlling epithelial cell proliferation and colony-forming capacity,
it has also been suggested that disruption of 15-PGDH expression
may be a required or important step for cancer cell adaptation to
the hypoxic tumor microenvironment and may promote survival
under the microenvironmental stress of glucose deprivation (11,
15). Furthermore, there is also a link between tumor-induced
immunosuppression and a deficiency of 15-PGDH expression,
with loss of 15-PGDH in tumor-infiltrating myeloid cells leading
to immune evasion (45). Perhaps the most convincing argument
in support of the development of small molecule activators
of 15-PGDH is the recognition that inactivation of 15-PGDH
serves as an important mechanism of resistance to celecoxib chemoprevention of colon tumors (46). Therefore, it is anticipated
that agents capable of enhancing the expression of 15-PGDH
may overcome resistance to celecoxib, creating a potential to
achieve a greater cancer chemopreventive benefit at a lower dose
of celecoxib. Studies focused on the potential synergistic effects
of celecoxib and triterpenoids may support the development of
a chemopreventive strategy that will combine these agents to
achieve maximal efficacy.
In Smad4Tko mice, expression of 15-PGDH was most likely suppressed in colon epithelial cells as a consequence of the soluble
mediators secreted during progressive colon inflammation. For
example, in mice with DSS-induced colitis, 15-PGDH was completely suppressed in the colonic mucosa. This observed reduction of 15-PGDH in Smad4Tko mice was reversible by treatment
with CDDO-Me, and reexpression of 15-PGDH was also accompanied by a reduction in the mucosal inflammatory process.
These results provide further evidence of the biological significance of 15-PGDH in colitis and CAC and point to a role for
15-PGDH as a key regulator of epithelial homeostasis during the
mucosal inflammatory process.
TGF-β signaling also plays a prominent role in the maintenance of mucosal epithelial and immune homeostasis. For example, the TGF-β signaling pathway has been identified recently as
a principal mediator of Wnt5a signaling, and both are required
for crypt regeneration after mucosal epithelial injury in mice (47).
TGF-β signaling is also known to protect against epithelial injury
in response to inflammatory mediators (48). CDDO-Me has
been shown to augment TGF-β signaling by potentiating phosphorylation of SMAD2/3 in various cells (31, 33, 36). We found
that exposure of colon epithelial cells to CDDO-Me results
in activation of SMAD2/3, suggesting that this triterpenoid augments an autocrine TGF-β signaling loop. Our observation that
the induction of 15-PGDH by CDDO-Me was antagonized by
inhibitors of the TGF-β receptor kinase or by a SMAD3-specific
inhibitor further supports this hypothesis and points to the importance of this signaling pathway as a relevant target of the triterpenoid class of small molecules.
The putative link between triterpenoid activity and TGF-β signaling may lead to questions regarding their potential clinical
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application, as the Markowitz lab and others have reported that
approximately 30% of human colorectal cancers have TGF-β type II
receptor mutations and over half of all human colorectal cancers
have signaling defects downstream of the receptors (18, 42, 43).
However, it is important to note that this emerging class of cancer
chemopreventive agents includes small molecules that are multifunctional and thus not selective for a specific target. Indeed, the
ability of the triterpenoids to directly impair STAT3 function, to
block NF-κB and mTOR signaling, and to activate Nrf2 (49–51)
may contribute directly to the observed clinical benefit noted in
the models of CAC we describe (52). Indeed, the capacity to
relieve repression of 15-PGDH by inflammatory mediators, such
as IFN-γ and IL-6, represents a complementary mechanism that
may work in tandem with direct SMAD-dependent activation of
15-PGDH in epithelial cells.
The synthetic triterpenoid, CDDO, was developed initially
through a small molecule screen for derivatives of oleanolic acid
with an enhanced capacity to block induction of iNOS by
IFN-γ (30). We have shown the imidazolide derivative of CDDO
suppresses STAT3 activation and induces apoptosis in cancer cells
(32). Here, we show in vivo administration of CDDO-Me effectively blocks the induction of IFN-γ and IL-6, suppresses STAT1
and STAT3 activation, and impairs induction of iNOS expression
in models of CAC. Thus, our data add further evidence to support
the relevance of the triterpenoid class of small molecules as agents
with a capacity for cancer chemoprevention. Given the association
among the loss of 15-PGDH expression, colon carcinogenesis,
and celecoxib resistance, further preclinical development of natural triterpenes and related synthetic derivatives as cancer chemopreventive agents is clearly warranted.
Methods
Materials. CDDO-Me was synthesized by Reata Pharmaceuticals. Recombinant human TGF-β1 was purchased from R&D Systems. SB431542 and
SIS3 were from Calbiochem. IL-6, IL-1, and TNF-α were obtained from
Peprotech. Anti-SMAD3, anti-SMAD2, anti–phospho-SMAD2, and anti–
phospho-SMAD3 were purchased from Cell Signaling. The anti–15-PGDH
antibody and 15-PGDH-pGL3 promoter vector were provided by Sanford D.
Markowitz (Case Western Reserve University and University Hospitals, Cleveland, Ohio, USA). Monoclonal anti–15-PGDH antibody was raised in rabbits
after injection of 15-PGDH protein purified from human placenta (13).
Animals and treatments. T cell–restricted deletion of the Smad4 gene in
mice has been described previously (34). Mice (C57BL/6 × SvEv129 × FVB)
homozygous for a SMAD4 conditional allele (Smad4co/co mice) (53) were bred
with mice expressing a transgene encoding a Cre recombinase driven by the
Lck promoter (Smad4co/co;Lck-cre mice) (54). Mice received 250 ng CDDO-Me
orally every other day for 1 month. Body weight was measured, and mice were
monitored for signs of rectal bleeding and diarrhea. After 4 weeks, mice were
sacrificed, sections were taken from colons for histological assessment, and
colon epithelial cell scrapings were taken for protein and RNA experiments.
For studies with DSS in this mouse model, 8-week-old SmadTko mice
received 2% DSS (MP Biomedicals) in drinking water for 7 days, followed
by regular drinking water for 10 days (repeated for 3 cycles). To determine whether CDDO-Me might suppress the development of colitis, after
3 cycles of DSS treatment, 250 ng CDDO-Me was given 3 times per week
by gavage for 4 weeks. For pathology, colon tissue samples were washed
with PBS, cut longitudinally, and then formalin fixed and paraffin embedded. For Western blot and RT-PCR analysis, epithelial cells were obtained
from scrapings of full-length colons, which were immediately frozen at
–80°C. All experiments were performed with 4 to 8 mice per group.
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Assessment of neoplasia and colitis. The colon was excised from the ileocecal junction to the anal verge, flushed several times with PBS (Gibco),
and opened longitudinally. Gross examination was performed to measure colon length and to evaluate tumor size. In addition, the incidence
(defined as number of mice with tumors per total mice in the group), the
mean number of tumors per mouse ± SD, and the mean tumor volume in
the group ± SD were calculated for each group. All colon tissue, including
tumors, was processed for histopathological evaluation and further biochemical analyses. All procedures were performed in a blinded manner.
Cell cultures and transient transfection and luciferase assay. The FET human
colon carcinoma cell line was a gift of Michael Brattain, Eppley Institute,
University of Nebraska, Lincoln, Nebraska, USA. Cells were cultured in
MEM (Invitrogen) with 10% FBS (Germini) and glutamine (2 mg/ml) at
37°C in 5% CO2. FET cells were seeded in 12-well plates at 1 × 105 cells per
well in triplicate and transiently transfected with 0.2 μg SBE promoter
vector or 2.5-kb 15-PGDH–PGL promoter vector and 20 ng CMV-renilla
using LipofectAMINE Plus as a transfection agent according to the manufacturer’s instructions (Invitrogen). Approximately 24 hours after transfection, cells were treated with either CDDO-Me (10–300 nM) or TGF-β
(1 ng/ml) for 24 hours in medium. Luciferase activity was measured using
the Promega Dual-Luciferase Assay Kit and a ML3000 Microtiter Plate Luminometer. Data shown represent the mean of 3 independent experiments.
Nitrite assay. NO levels were measured by photometric analysis by using
a Nitrite/Nitrate Assay Kit (Cayman Chemical). Sera were centrifuged for
45 minutes at 2,000 g through an ultrafilter (Centricon, Millipore).
Nitrate in the supernatant was reduced to nitrite by incubation with
nitrate reductase and NADPH at room temperature for 1 hour. Nitrite concentration in the reduced samples was measured by the Griess reaction
and calculated by comparison with standard solutions of sodium nitrite
prepared in saline solution after reduction of nitrate.
RT-PCR analysis. TRIzol reagent (Invitrogen) was used for the isolation
of total RNA. For RT-PCR, the One-Step RT-PCR Kit (Invitrogen) was
used according to the manufacturer’s instructions. Samples were normalized with β-actin mRNA levels. PCR products were analyzed by agarose
gel electrophoresis in the presence of ethidium bromide. The products
of amplification were visualized with a UV transilluminator.
Western blotting. Confluent cells cultured in 6-well tissue culture plates
were treated with CDDO-Me and/or TGF-β for 24 hours at 37°C. After
treatment, cells were harvested and lysed by incubation in lysis buffer
(150 mM NaCl, 20 mM Tris-Cl pH 7.5, 1 mM PMSF, 1 mM Na 3VO4,
25 mM NaF, 1% aprotinin, 10 μg/ml leupeptin) on ice for 30 minutes. 20 μg aliquots of protein were separated by electrophoresis in
10% SDS/PAGE minigels, followed by electrophoretic protein transfer
to nitrocellulose membrane (Invitrogen). Nonspecific binding of antibody was prevented by incubating the membranes for 1 hour in block1. Kappelman MD, Moore KR, Allen JK, Cook SF.
Recent trends in the prevalence of Crohn’s disease
and ulcerative colitis in a commercially insured US
population. Dig Dis Sci. 2012;58(2):519–525.
2. [No authors listed]. Epidemiological and clinical
features of Spanish patients with Crohn’s disease.
Spanish Epidemiological and Economic Study
Group on Crohn’s disease. Eur J Gastroenterol Hepatol. 1999;11(10):1121–1127.
3. Molodecky NA, et al. Increasing incidence and
prevalence of the inflammatory bowel diseases
with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.
4. Gersemann M, Wehkamp J, Stange EF. Innate
immune dysfunction in inflammatory bowel disease. J Intern Med. 2012;271(5):421–428.
5. Boirivant M, Cossu A. Inflammatory bowel disease.
Oral Dis. 2012;18(1):1–15.

ing buffer (TBST, 0.05% Tween-20), followed by incubation with buffer
containing the primary antibody. Membranes were washed 3 times in
TBST-Tween-20 buffer (0.05% Tween-20) and incubated for 1 hour at
room temperature with the horseradish peroxidase–conjugated secondary antibodies. After washing the membranes, immunostaining was
visualized by ECL. Films of scanned images were quantified using ImageJ
software (developed at the National Institute of Mental Health, NIH).
Histology. Colons were removed, flushed with PBS, fixed in 10% formalin, and embedded in paraffin wax. Sections were stained with H&E
and examined by light microscopy. Assessment of tumor number was
performed in a blinded fashion. Tumor size was calculated using a digital
eyepiece, and the greatest width of each tumor was measured and recorded.
FACS analysis. Cell suspensions were prepared from spleens and lymph
nodes filtered through 40-μm nylon mesh. Erythrocytes were lysed using
ACK lysis buffer (BioWhittaker), and cells were washed twice in RPMI
1640 supplemented with 10% heat-inactivated FBS, 50 μM 2-Me, penicillin, and streptomycin (GIBCO/Life Sciences). Viable cells were counted
using trypan blue exclusion and a hemacytometer. Antibodies used in
FACS analyses and in purification of pan T cells were purchased from
BD Pharmingen. Pan T cells were isolated using a Pan T Cell Isolation
Kit according to the manufacturer’s instruction (purity greater than 95%).
Statistics. Data are expressed as mean ± SEM. Statistical significance
was determined by 1-way ANOVA with Tukey-Kramer multiple comparisons test. Fisher’s exact probability test was used for comparison of the
incidence of lesions between the 2 groups. P values of less than 0.05 were
considered significant.
Study approval. All animal experiments were performed in accordance
with institutional guidelines and with approval of Institutional Animal
Care and Use Committees at Case Western Reserve University.
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